Prognostic factors for patients treated with abiraterone

Prognostic factors for patients treated with abiraterone

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evalua...

Full description

Saved in:

Bibliographic Details
Main Authors:	Cecília M Alvim, André Mansinho, Rita S Paiva, Raquel Brás, Patrícia M Semedo, Soraia Lobo-Martins, Carolina B da Ponte, Daniela Macedo, Leonor Ribeiro, José P dos Reis, Isabel Fernandes, Luís Costa
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2020-02-01
Series:	Future Science OA
Subjects:	abiraterone acetate metastatic castration-resistant prostate cancer prostate-specific antigen response
Online Access:	https://www.future-science.com/doi/10.2144/fsoa-2019-0079
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Oral mucositis with abiraterone acetate: A therapeutic dilemma
by: Shaunak Valame, et al.
Published: (2020-01-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Metastatic Castrate-Sensitive Prostate Cancer Patients Treated with Abiraterone Acetate
by: Caio Vinícius Suartz, et al.
Published: (2024-08-01)

A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer
by: Xiaolin Lu, et al.
Published: (2025-05-01)

Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer
by: Kaichen Zhou, et al.
Published: (2025-04-01)

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-world settings
by: Armen Aprikian, et al.
Published: (2025-02-01)

Prescription pattern of abiraterone in Brazil - a survey of medical oncologists
by: João Pedro Homse-Netto, et al.
Published: (2023-08-01)

A Super‐Enhancer‐Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration‐Resistant Prostate Cancer
by: Liling Jiang, et al.
Published: (2025-08-01)

Short-term efficacy of enzalutamide in treatment of patients with abiraterone-resistant metastatic castration-resistant prostate cancer
by: MEI Jingchang, SU Xiaonan, YAO Yu, GUAN Fengju, ZHANG Guiming
Published: (2025-02-01)

Case Report: Abiraterone in brain metastases from prostate cancer
by: Tobias Peres, et al.
Published: (2025-04-01)

Efficacy and safety of darolutamide versus abiraterone acetate plus prednisone in combination with ADT for mHSPC: a real-world clinical retrospective study
by: Ting Hu, et al.
Published: (2025-06-01)

Serum CDC42 level change during abiraterone plus prednisone treatment and its association with prognosis in metastatic castration-resistant prostate cancer patients
by: Yong Ma, et al.
Published: (2025-03-01)

A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer
by: Pongwut Danchaivijitr, et al.

SURVIVAL EFFECT OF PALLIATIVE RADIOTHERAPY IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER DEVELOPING OLIGO-PROGRESSION UNDER ANTIANDROGEN TREATMENT
by: Sabin Göktaş Aydın, et al.
Published: (2023-03-01)

Prognostic Nutritional Index and a Blood-Based Prognostic Tool in Prostate Cancer Treated with Abiraterone, Enzalutamide or Cabazitaxel
by: Hakan Taban, et al.
Published: (2025-06-01)

Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients
by: N. K. Mazina, et al.
Published: (2017-11-01)

Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer
by: N. A. Avxentyev, et al.
Published: (2019-01-01)

Adrenal Insufficiency Induced by Continued Abiraterone Acetate Use in a Prostate Cancer Patient in Remission: The Dangers of Unmonitored Long-Term Therapy Without Corticosteroids
by: Ahmed S. Mohamed, et al.
Published: (2025-03-01)

Dysphasia: metastatic prostate cancer to the leptomeninges: a case report
by: Diana Jodeh, et al.
Published: (2024-10-01)

Clinicoradiological profile and treatment outcomes in prostate cancer at a tertiary care cancer center in India
by: Astha Rajput, et al.
Published: (2020-01-01)

Physician and Patient Preferences for the Treatment of Metastatic Castration-Sensitive and Castration-Resistant Prostate Cancer: A Best-Worst Scaling Study in Japan
by: Takahiro Kimura, et al.
Published: (2025-02-01)

Therapeutic outcomes of enzalutamide-docetaxel combination versus docetaxel monotherapy in post-sequential androgen receptor axis-targeted therapy failure metastatic castration-resistant prostate cancer
by: Zhiyu Zhang, et al.
Published: (2025-08-01)

Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
by: Himisha Beltran, et al.
Published: (2025-08-01)

Synergistic anticancer effect of CDRI-08 and Abiraterone acetate against castration resistant prostate cancer targeting PI3K/Akt pathway
by: Bhavana Jonnalagadda, et al.
Published: (2025-09-01)

Experience with using fosfestrol for treating metastatic castrate-resistant prostate cancer in resource-limited setting
by: Jayachandran Perumal Kalaiyarasi, et al.
Published: (2019-01-01)

Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022
by: D. A. Andreev, et al.
Published: (2022-06-01)

Multicenter, international, retrospective study of prognostic factors for Ra223
by: Takuya Oishi, et al.
Published: (2025-03-01)

Clinical observations of patients with metastatic castration-resistant prostate cancer living in the Tambov region
by: P. G. Berezin, et al.
Published: (2023-09-01)

Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer
by: Martin Boegemann, et al.
Published: (2025-07-01)

Combined treatment with anti-PSMA antibody and human peripheral blood-derived NK cells for castration-resistant prostate cancer
by: Fangming Wang, et al.
Published: (2025-05-01)

MAIN MOLECULAR TARGETS FOR PROSTATE CANCER THERAPY
by: G. S. Krasnov, et al.
Published: (2016-02-01)

LU-177-PSMA TREATMENT FOR METASTATIC PROSTATE CANCER – CASE EXAMPLES OF MIRACLE RESPONSES
by: K. Kairemo, et al.
Published: (2018-03-01)

Adverse prognosis gene expression patterns in metastatic castration‐resistant prostate cancer
by: Marina N. Sharifi, et al.
Published: (2025-08-01)

Assessing the clinical outcomes of immunotherapy and docetaxel combinations in metastatic castration-resistant prostate cancer: a meta-analysis
by: Azka Syed, et al.
Published: (2025-07-01)

Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis
by: Brigida Anna Maiorano, et al.
Published: (2025-02-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

USE OF <sup>177</sup>Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER
by: A. A. Medvedeva, et al.
Published: (2021-06-01)

PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis
by: Ray Manneh, et al.
Published: (2025-07-01)

Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
by: Ze Wang, et al.
Published: (2025-08-01)

Usefulness of prostate specific antigen density in detecting prostate carcinoma: A hospital-based study in patients with prostate biopsies
by: Reshmi Shrestha, et al.
Published: (2022-03-01)